We held our Autumn Shareholder Reception at Calla Lily Clinical Care’s London HQ yesterday with shareholders, advisors and our team all in one room, and with a good deal to report. Approaching completion of our FREEDOM clinical trial for Callavid®. A new second use case funded by Wellcome Leap, taking our drug delivery platform into …

An inspiring visit to the Ragon Institute of Mass General Brigham, MIT, and Harvard catching up with Professor Doug Kwon and Meilin Zhu. Doug’s lab is at the front of the vaginal microbiome field: strain-level work on Lactobacillus, and more recently a Cell Host & Microbe paper on which host and microbial factors determine whether …

Our Dr Lara Zibners joins the UNC Center for the Business of Health Leadership Board. As noted by the Center: Lara is a board-certified pediatrician and pediatric emergency medicine specialist, she brings more than two decades of experience spanning clinical practice, medical education, and media, is an award-winning author, and proud alumus of UNC Kenan-Flagler …

Our co-founder Dr Lara Zibners and Dr Adam Brown of ABIG Health have published a white paper on why menopause education belongs in core medical school curriculum, not at the margins of it. 58% of medical textbooks worldwide never mention menopause. Only 31.3% of OBGYN residency programs have a menopause curriculum. Please have a read …

🇺🇲 We’ll be at the American Drug Delivery & Formulation Summit in Boston, 14–15 September. Callavid® is an intravaginal drug delivery platform, at clinical stage with progesterone delivery for threatened miscarriage and IVF support. A further development programme covers locally delivered antibiotics for UTI and AMR. Future applications include gynaecological cancers, menopause-related indications, HIV prophylaxis …

It really matters who is in the room you’re in. Two years ago Lara and I pitched at the inaugural Merck Healthcare / M Ventures W Accelerate Innovation programme run by W Group The event was fantastic. The seniority of the people in that room were impressive, and the conversations that started there became the …

Day Two of the Oxford Summer Academy for the Social Science of Health Innovation (SASHI)– The Women’s Health Revolution: Women’s and Reproductive Health Equity –held at St Hilda’s College, University of Oxford 🏛️ Great to return to Oxford for a fireside chat with Dr Emma Thornton. I talked about exciting progress on our progesterone-Callavid® clinical …

Original article here Calla Lily joins $50M program targeting antibiotic resistance A new intravaginal drug delivery platform has been selected to investigate whether localized UTI treatment can reduce the collateral effects of systemic antibiotics. Written by Bree Foster, PhD Aug 11, 2026 New approaches aim to target infections while sparing the gut microbiome. credit: istock.com/Scharvik …

It was great to attend Formulation & Delivery Europe 2026 in Basel last month – a valuable opportunity to explore the latest industry trends in drug formulation and delivery, connect with industry experts to build collaborations, and discuss the technologies shaping the future of healthcare. Innovation is moving quickly in combination products and alternative routes …

We do not believe many other London based start-ups have their own labs to be able to manufacture products, but here at Calla Lily Clinical Care, we have done exactly that. All of our Callavid® design validation and clinical trial products started their production here in London. Now that our clinical trial is underway, our …